<?xml version="1.0" encoding="UTF-8"?>
<p>The live attenuated dengue vaccine TAK-003 (DENVax or TDV) is developed by Takeda Vaccine Incorporated. It is comprised of one attenuated dengue-2 viruses, and three other chimeras that contain prM and E genes of other three serotypes built on the backbone of attenuated DENV-2 (
 <xref rid="B135" ref-type="bibr">Osorio et al., 2015</xref>). Here, the backbone DENV-2 in TAK-003 is derived from dengue-2 attenuated virus strain PDK-53, which was obtained through serially passaging of DENV-2 16681 in primary dog kidney cells for 53 times (
 <xref rid="B12" ref-type="bibr">Bhamarapravati et al., 1987</xref>). This tetravalent vaccine has non-structural proteins of DENV-2, and it is capable of activating DENV-2 NS1 specific T cell responses and antibodies (
 <xref rid="B167" ref-type="bibr">Sharma et al., 2019</xref>), both of which 
 <italic>Dengvaxia</italic> is incapable of inducing. But among tetravalent immune responses elicited by the chimeric TDV, the immunity to DENV-4 was the lowest when testing in Phase I and Phase II studies of tetravalent TDV formulations (
 <xref rid="B136" ref-type="bibr">Osorio et al., 2014</xref>; 
 <xref rid="B57" ref-type="bibr">George et al., 2015</xref>; 
 <xref rid="B168" ref-type="bibr">Sirivichayakul et al., 2016</xref>). Moreover, in the released data from part 1 of its ongoing phase III study, the efficacy of TAK-003 to DENV-4 was still unclear for the insufficient case numbers of DENV-4 infection during study (
 <xref rid="B14" ref-type="bibr">Biswal et al., 2019</xref>). Irrespective of this shortfall, the merits of this vaccine warrants its further testing in several Phase III trials in endemic regions.
</p>
